3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

HumanKine™ Interferon α 2B, human recombinant, expressed in HEK 293 cells

Catalog Number **H6166**
Storage Temperature –20 °C

Synonyms: IFN-α 2B, IFN

Product Description

HumanKine™ IFN α 2B is a glycosylated monomer with an apparent molecular mass of 16 kDa. Production in human 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.

IFN α 2B belongs to the type I interferon protein family. It is produced by many cell types in response to viral infection. IFN α 2B has antiproliferative and antitumor activities, as well as induction of apoptosis and the inflammatory response. It enhances the expression of MHC proteins by increasing the presentation of antigen peptides and activates cytotoxic T-cells.

This product is lyophilized from a PBS solution.

ED_{50}: ≤0.16 ng/mL

The specific activity was determined by the dose-dependent cytotoxicity of the human TF-1 cell line (human erythroleukemic indicator cell line).

Purity: ≥95% (SDS-PAGE)

Endotoxin level: ≤1 EU/µg

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.

Storage/Stability

Store the product at –20 °C. The lyophilized product remains active for one year at –20 °C. Upon reconstitution, the cytokine can be stored at 2–8 °C for short term only, or at –20 °C to –80 °C in aliquots for long term. Avoid repeated freeze-thaw cycles.

References

1. Mire-Sluis, A.R. et al., J. Immunol. Methods, **195**, 55-61 (1996).
2. Bogdan, C. et al., Immunol. Rev., **202**, 33-48 (2004).

GS,JF,MAM 12/10-1